Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Adaptimmune Therapeutics

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies

AstraZeneca

Johnson & Johnson

Pfizer

Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage.

4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam

Roche's (RHHBY) Sparks enters into a collaboration agreement with NeuExcell Therapeutics to develop a novel gene therapy for HD.

Roche's (RHHBY) Sparks Set to Develop Gene Therapy for HD

Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD). Spark Therapeutics is a part of Roche Holdings AG (OTC: RHHBY).

Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy

Basel, 07 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new oncology data will be presented at the European Society for Medical Oncology (ESMO) Congress, which will be held 16-21 September, 2021. With one of the broadest oncology pipelines and portfolios in the industry, Roche presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung cancer, and a presentation on cancer of unknown primary (CUP), which has been selected for inclusion in the ESMO Press Programme.

Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new oncology data will be presented at the European Society for Medical Oncology (ESMO) Congress, which will be held September 16-21, 2021. With one of the broadest oncology pipelines and portfolios in the industry, Genentech presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung cancer, and a presentation

Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers

STATE COLLEGE, Pa. and PHILADELPHIA, Sept.

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

Amazon

Aspen Technology Inc

Alibaba

Bayer AG

Baidu

British American Tobacco

Anheuser-Busch InBev

Campbell Soup

Enterprise Products Partners

GlaxoSmithKline

Imperial Brands PLC

Intel

Kellogg

Lockheed Martin

Merck

Polaris

Reckitt Benckiser Group PLC

Sanofi

Tencent Holdings Limited

Western Union

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The September 2021 Heat Map

Else Nutrition Holdings Inc.. has said it will be expanding into Roche Bros.

Else Nutrition expands its Plant-Based Complete Nutrition for Toddlers into Roche Bros. locations this September

JOHANNESBURG--(BUSINESS WIRE)--Roche and the Kolisi Foundation today launched a children's book, Keto and Zuri Learn about COVID-19, that will help parents and caregivers across Africa explain COVID-19 to children by sharing scientific facts in age-appropriate language. The book is available to download for free on both the Kolisi Foundation and Roche's websites, and a limited run of free printed copies will be distributed throughout Africa in seven languages. “We recognize the confusion and co

Roche Partners with the Kolisi Foundation, One By One Target Covid Campaign and Transnet to Launch Free COVID-19 Children's Book

Roche (RHHBY) will withdraw Tecentriq for treating adults with unresectable locally advanced or metastatic triple-negative breast cancer in the United States.

Roche (RHHBY) Withdraws Tecentriq for Breast Cancer in the U.S.

Following a consultation from the FDA, Roche Holdings AG (OTC: RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type of breast cancer in the U.S. Earlier this year, Roche withdrew the drug from the U.S. to treat bladder cancer after follow-up studies failed to meet goals.

After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US

Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency's assessment of the current mTNBC treatment landscape and in accordance with the requirements of the accelerated approval programme. This decision only impacts the mTNBC indication in the US. It does not affect other approved indications for Tecentriq in the US and outside the US, including mTNBC. This is not related to any changes in either the efficacy or safety associated with Tecentriq.

Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has made the decision to voluntarily withdraw the U.S. accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1, as determined b

Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Axsome Therapeutics

Nasdaq

Novavax

Pieris Pharma

Cassava Sciences Inc

Seagen

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Which Biotech Stock Will Shock the Market in 2022?

Shape Therapeutics has signed a deal potentially exceeding $3 billion with pharma giant Roche to support the development of gene therapies for Alzheimer's and Parkinson's disease, the Seattle company announced Wednesday.

Seattle biotech firm Shape Therapeutics inks gene therapy deal with Roche worth up to $3B

Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC: RHHBY) for RNA editing technology.  Through this partnership, ShapeTX will apply its proprietary RNA editing platform RNAfix and potentially leverage its AAVid technology platform to develop gene therapy for certain targets in certain targets areas of Alzheimer's disease, Parkinson's disease, and rare diseases.

Shape Therapeutics, Roche Form $3B RNA Editing Collaboration

AbbVie

Roche Holding AG ( RHHBY , Financial) sits atop the list of pharmaceutical companies that are getting the most out of research and development spending. That's an important consideration for investors given new products with blockbuster potential are the lifeblood of the industry.

Roche, AbbVie Top R&D Productivity in Past 5 Years

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 185,000 shares of Swiss multinational health care company Roche on Friday, as the share price of the fund traded up over 1% in the day's session.

Cathie Wood's ARK Invest Sells Over 185,000 Shares of Roche

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 175,000 shares of Roche Holding AG (NYSEARCA: RHHBY) on Thursday, as the share price of this fund traded down nearly 2% in the day's session.

Cathie Wood's ARK Invest Sells Over 175,000 Shares of Roche

Regeneron Pharmaceuticals

The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent and treat COVID-19. The U.K. chief medical officers confirmed the antibody would be rolled out on the National Health Service in the coming weeks.

UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail

Analog Devices

Analog Devices, Inc. (ADI) CEO Vince Roche on Q3 2021 Results - Earnings Call Transcript

Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR proteins in tumours to provide important treatment information to clinicians. MMR is a naturally occurring mechanism that scans our DNA, correcting errors that cause disease. When MMR is deficient (dMMR), cells mutate, which can lead to cancer. While MMR deficiency is most common in endometrial cancer, other high prevalence dMMR tumour types include gastric, colorectal, small intestine, cervical and neuroendocrine cancers. In the U.S., prevalence of dMMR across patients with solid tumours has been estimated at 14 percent.3 PD-1 inhibitors can be effective treatment in cancers with MMR deficiency. "As the first companion diagnostic of its kind, this test can help qualify patients with solid tumours that are deficient in MMR who have progressed in their disease and who have no other suitable treatment options,” said Thomas Schinecker, CEO Roche Diagnostics. “Based on the results of our MMR biomarker test, these patients may be eligible to receive GSK's JEMPERLI. We are pleased that our innovative companion diagnostic label continues to grow to serve more patients.” FDA approval of the VENTANA MMR RxDx Panel provides clinicians with access to a fully automated panel of MMR biomarkers tested by immunohistochemistry (IHC), enabling impactful treatment decisions for patients. JEMPERLI was approved by the FDA on 17 August 2021 for the treatment of adult patients with dMMR recurrent or advanced solid tumours, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This indication received accelerated approval based on tumour response rate and durability of response. Continued approval for this indication may depend on verification and description of clinical benefit in a confirmatory trial(s).The VENTANA MMR RxDx Panel and JEMPERLI were earlier approved by the FDA for use in endometrial cancer in April 2021. Read more about Roche innovation in MMR biomarker testing. A bout the VENTANA MMR RxDx Panel The VENTANA MMR RxDx Panel is a label expansion of Roche's current on-market VENTANA MMR IHC Panel. The VENTANA MMR RxDx Panel is intended for the assessment of expression of MMR proteins in formalin-fixed, paraffin-embedded (FFPE) tumour tissue stained with OptiView DAB IHC Detection Kit and ancillary reagents in the panel for VENTANA anti-MLH1 (M1), VENTANA anti-MSH2 (G219-1129) and VENTANA anti-MSH6 (SP93) and OptiView DAB IHC Detection Kit with the OptiView Amplification Kit and ancillary reagents for VENTANA anti-PMS2 (A16-4) on a BenchMark ULTRA instrument. DNA mismatch repair (MMR) proteins have been clinically proven to be predictive biomarkers for PD-1 targeted therapy; specifically, a loss of expression of one or more MMR proteins might predict an increased likelihood of response to such therapy.4,5,6 PD-1 inhibitors can be effective in cancers with MMR deficiency.4,6 MMR is a conserved molecular mechanism that functions to correct the improper base substitutions that spontaneously occur during DNA replication. Defects in the MMR machinery have been attributed to mutations in the MMR proteins. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020:70(1):7-30.[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019:69(1):7-34[3] Lorenzi M, Amonkar M, Zhang J, et al. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020. doi.org/10.1155/2020/1807929 [4] Lee YC, S Lheureux, and AM Oza. Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol. 2017:29:47-58.[5] GSK website, https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/[6] Kato M, Takano M, Miyamoto M, et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol. 2015:26(1):40-45. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy

Roche Holding AG ROG, +0.45% said Monday that Actemra, its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short supply and will be so for weeks or months. The drug "has been widely used to treat hospitalized patients with severe or critical COVID-19 around the world, and demand for this medicine has increased to unprecedented levels globally," the company said.

Roche says arthritis drug authorized to treat hospitalized COVID-19 patients is in short supply

Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after showing it cut the risk of death.  Less than two months after that development, the company is running out of supplies of the drug.

News for Roche Holding AG Stock (RHHBY)